Compare Elder Pharma with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA GLENMARK PHARMA ELDER PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x -0.2 10.1 - View Chart
P/BV x 0.1 1.4 7.0% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ELDER PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
GLENMARK PHARMA
Mar-19
ELDER PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs380712 53.4%   
Low Rs188484 38.9%   
Sales per share (Unadj.) Rs491.2349.6 140.5%  
Earnings per share (Unadj.) Rs-3.232.8 -9.7%  
Cash flow per share (Unadj.) Rs14.444.3 32.5%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs376.5198.6 189.5%  
Shares outstanding (eoy) m20.54282.17 7.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.61.7 33.8%   
Avg P/E ratio x-89.318.2 -489.7%  
P/CF ratio (eoy) x19.713.5 146.2%  
Price / Book Value ratio x0.83.0 25.1%  
Dividend payout %06.1 0.0%   
Avg Mkt Cap Rs m5,833168,625 3.5%   
No. of employees `000NA12.0 0.0%   
Total wages/salary Rs m2,17920,561 10.6%   
Avg. sales/employee Rs ThNM8,196.0-  
Avg. wages/employee Rs ThNM1,708.1-  
Avg. net profit/employee Rs ThNM768.5-  
INCOME DATA
Net Sales Rs m10,08998,655 10.2%  
Other income Rs m2572,081 12.3%   
Total revenues Rs m10,346100,736 10.3%   
Gross profit Rs m-79215,858 -5.0%  
Depreciation Rs m3613,259 11.1%   
Interest Rs m2,7563,346 82.4%   
Profit before tax Rs m-3,65311,335 -32.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7131,672 222.1%   
Tax Rs m1253,756 3.3%   
Profit after tax Rs m-659,250 -0.7%  
Gross profit margin %-7.816.1 -48.8%  
Effective tax rate %-3.433.1 -10.3%   
Net profit margin %-0.69.4 -6.9%  
BALANCE SHEET DATA
Current assets Rs m9,24066,968 13.8%   
Current liabilities Rs m9,99840,211 24.9%   
Net working cap to sales %-7.527.1 -27.7%  
Current ratio x0.91.7 55.5%  
Inventory Days Days4683 55.6%  
Debtors Days Days6081 73.8%  
Net fixed assets Rs m10,12433,322 30.4%   
Share capital Rs m206282 72.9%   
"Free" reserves Rs m5,58255,770 10.0%   
Net worth Rs m7,73456,052 13.8%   
Long term debt Rs m4,88935,738 13.7%   
Total assets Rs m22,882132,888 17.2%  
Interest coverage x-0.34.4 -7.4%   
Debt to equity ratio x0.60.6 99.2%  
Sales to assets ratio x0.40.7 59.4%   
Return on assets %11.89.5 124.1%  
Return on equity %-0.816.5 -5.1%  
Return on capital %22.317.8 125.2%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30762,998 0.5%   
Fx outflow Rs m12522,859 0.5%   
Net fx Rs m18140,140 0.5%   
CASH FLOW
From Operations Rs m11,75413,242 88.8%  
From Investments Rs m-561-6,990 8.0%  
From Financial Activity Rs m-6,762-7,387 91.5%  
Net Cashflow Rs m4,432-2,971 -149.2%  

Share Holding

Indian Promoters % 39.6 48.3 82.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 6.9 108.7%  
FIIs % 16.8 34.4 48.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 10.5 343.8%  
Shareholders   16,479 56,727 29.0%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   PROCTER & GAMBLE HEALTH  CIPLA  TORRENT PHARMA  SUVEN LIFESCIENCES  WYETH LTD  

Compare ELDER PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

DHFL Saga, Falling Passenger Vehicle Sales, and Top Cues in Focus Today(Pre-Open)

Indian share markets witnessed buying interest on Friday and ended their volatile trading session on a positive note.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - FDC LTD. COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS